Cargando…

Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database

SIMPLE SUMMARY: BRCA-mutated high-grade epithelial ovarian cancers represent a specific subset of gynecological malignancies. Real-world comprehensive data have been elusive to date. As such, we conducted a comprehensive description of clinicopathological and therapeutical characteristics via the Ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Bini, Marta, Quesada, Stanislas, Meeus, Pierre, Rodrigues, Manuel, Leblanc, Eric, Floquet, Anne, Pautier, Patricia, Marchal, Frédéric, Provansal, Magali, Campion, Loïc, Causeret, Sylvain, Gourgou, Sophie, Ray-Coquard, Isabelle, Classe, Jean-Marc, Pomel, Christophe, De La Motte Rouge, Thibault, Barranger, Emmanuel, Savoye, Aude Marie, Guillemet, Cécile, Gladieff, Laurence, Demarchi, Martin, Rouzier, Roman, Courtinard, C, Romeo, Clémence, Joly, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406396/
https://www.ncbi.nlm.nih.gov/pubmed/36011033
http://dx.doi.org/10.3390/cancers14164040
_version_ 1784774110663933952
author Bini, Marta
Quesada, Stanislas
Meeus, Pierre
Rodrigues, Manuel
Leblanc, Eric
Floquet, Anne
Pautier, Patricia
Marchal, Frédéric
Provansal, Magali
Campion, Loïc
Causeret, Sylvain
Gourgou, Sophie
Ray-Coquard, Isabelle
Classe, Jean-Marc
Pomel, Christophe
De La Motte Rouge, Thibault
Barranger, Emmanuel
Savoye, Aude Marie
Guillemet, Cécile
Gladieff, Laurence
Demarchi, Martin
Rouzier, Roman
Courtinard, C
Romeo, Clémence
Joly, Florence
author_facet Bini, Marta
Quesada, Stanislas
Meeus, Pierre
Rodrigues, Manuel
Leblanc, Eric
Floquet, Anne
Pautier, Patricia
Marchal, Frédéric
Provansal, Magali
Campion, Loïc
Causeret, Sylvain
Gourgou, Sophie
Ray-Coquard, Isabelle
Classe, Jean-Marc
Pomel, Christophe
De La Motte Rouge, Thibault
Barranger, Emmanuel
Savoye, Aude Marie
Guillemet, Cécile
Gladieff, Laurence
Demarchi, Martin
Rouzier, Roman
Courtinard, C
Romeo, Clémence
Joly, Florence
author_sort Bini, Marta
collection PubMed
description SIMPLE SUMMARY: BRCA-mutated high-grade epithelial ovarian cancers represent a specific subset of gynecological malignancies. Real-world comprehensive data have been elusive to date. As such, we conducted a comprehensive description of clinicopathological and therapeutical characteristics via the Epidemiological Strategy and Medical Economics (ESME) data warehouse, which collects data from 18 French comprehensive cancer centers from the Unicancer network. This led to useful findings regarding the natural disease history of these patients in clinical practice, prior to the advent of poly-ADP ribose polymerase inhibitors. ABSTRACT: Background: In spite of the frequency and clinical impact of BRCA1/2 alterations in high-grade epithelial ovarian cancer (HGEOC), real-world information based on robust data warehouse has been scarce to date. Methods: Consecutive patients with BRCA-mutated HGEOC treated between 2011 and 2016 within French comprehensive cancer centers from the Unicancer network were extracted from the ESME database. The main objective of the study was the assessment of clinicopathological and treatments parameters. Results: Out of the 8021 patients included in the ESME database, 266 patients matching the selection criteria were included. BRCA1 mutation was found in 191 (71.8%) patients, while 75 (28.2%) had a BRCA2 mutation only; 95.5% of patients received a cytoreductive surgery. All patients received a taxane/platinum-based chemotherapy (median = six cycles). Complete and partial response were obtained in 53.3% and 20.4% of the cases, respectively. Maintenance therapy was administered in 55.3% of the cases, bevacizumab being the most common agent. After a median follow up of 51.7 months, a median progression-free survival of 28.6 months (95% confidence interval (CI) [26.5; 32.7]) and an estimated 5-year median overall survival of 69.2% (95% CI [61.6; 70.3]) were reported. Notably, BRCA1- and BRCA2-mutated cases exhibited a trend towards different median progression-free survivals, with 28.0 (95% CI [24.4; 32.3]) and 33.3 months (95% CI [26.7; 46.1]), respectively (p-value = 0.053). Furthermore, five-year OS for BRCA1-mutated patients was 64.5% (95% CI [59.7; 69.2]), while it was 82.5% (95% CI [76.6; 88.5]) for BRCA2-mutated ones (p-value = 0.029). Conclusions: This study reports the largest French multicenter cohort of BRCA-mutated HGEOCs based on robust data from the ESME, exhibiting relevant real-world data regarding this specific population.
format Online
Article
Text
id pubmed-9406396
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94063962022-08-26 Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database Bini, Marta Quesada, Stanislas Meeus, Pierre Rodrigues, Manuel Leblanc, Eric Floquet, Anne Pautier, Patricia Marchal, Frédéric Provansal, Magali Campion, Loïc Causeret, Sylvain Gourgou, Sophie Ray-Coquard, Isabelle Classe, Jean-Marc Pomel, Christophe De La Motte Rouge, Thibault Barranger, Emmanuel Savoye, Aude Marie Guillemet, Cécile Gladieff, Laurence Demarchi, Martin Rouzier, Roman Courtinard, C Romeo, Clémence Joly, Florence Cancers (Basel) Article SIMPLE SUMMARY: BRCA-mutated high-grade epithelial ovarian cancers represent a specific subset of gynecological malignancies. Real-world comprehensive data have been elusive to date. As such, we conducted a comprehensive description of clinicopathological and therapeutical characteristics via the Epidemiological Strategy and Medical Economics (ESME) data warehouse, which collects data from 18 French comprehensive cancer centers from the Unicancer network. This led to useful findings regarding the natural disease history of these patients in clinical practice, prior to the advent of poly-ADP ribose polymerase inhibitors. ABSTRACT: Background: In spite of the frequency and clinical impact of BRCA1/2 alterations in high-grade epithelial ovarian cancer (HGEOC), real-world information based on robust data warehouse has been scarce to date. Methods: Consecutive patients with BRCA-mutated HGEOC treated between 2011 and 2016 within French comprehensive cancer centers from the Unicancer network were extracted from the ESME database. The main objective of the study was the assessment of clinicopathological and treatments parameters. Results: Out of the 8021 patients included in the ESME database, 266 patients matching the selection criteria were included. BRCA1 mutation was found in 191 (71.8%) patients, while 75 (28.2%) had a BRCA2 mutation only; 95.5% of patients received a cytoreductive surgery. All patients received a taxane/platinum-based chemotherapy (median = six cycles). Complete and partial response were obtained in 53.3% and 20.4% of the cases, respectively. Maintenance therapy was administered in 55.3% of the cases, bevacizumab being the most common agent. After a median follow up of 51.7 months, a median progression-free survival of 28.6 months (95% confidence interval (CI) [26.5; 32.7]) and an estimated 5-year median overall survival of 69.2% (95% CI [61.6; 70.3]) were reported. Notably, BRCA1- and BRCA2-mutated cases exhibited a trend towards different median progression-free survivals, with 28.0 (95% CI [24.4; 32.3]) and 33.3 months (95% CI [26.7; 46.1]), respectively (p-value = 0.053). Furthermore, five-year OS for BRCA1-mutated patients was 64.5% (95% CI [59.7; 69.2]), while it was 82.5% (95% CI [76.6; 88.5]) for BRCA2-mutated ones (p-value = 0.029). Conclusions: This study reports the largest French multicenter cohort of BRCA-mutated HGEOCs based on robust data from the ESME, exhibiting relevant real-world data regarding this specific population. MDPI 2022-08-21 /pmc/articles/PMC9406396/ /pubmed/36011033 http://dx.doi.org/10.3390/cancers14164040 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bini, Marta
Quesada, Stanislas
Meeus, Pierre
Rodrigues, Manuel
Leblanc, Eric
Floquet, Anne
Pautier, Patricia
Marchal, Frédéric
Provansal, Magali
Campion, Loïc
Causeret, Sylvain
Gourgou, Sophie
Ray-Coquard, Isabelle
Classe, Jean-Marc
Pomel, Christophe
De La Motte Rouge, Thibault
Barranger, Emmanuel
Savoye, Aude Marie
Guillemet, Cécile
Gladieff, Laurence
Demarchi, Martin
Rouzier, Roman
Courtinard, C
Romeo, Clémence
Joly, Florence
Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
title Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
title_full Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
title_fullStr Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
title_full_unstemmed Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
title_short Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
title_sort real-world data on newly diagnosed brca-mutated high-grade epithelial ovarian cancers: the french national multicenter esme database
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406396/
https://www.ncbi.nlm.nih.gov/pubmed/36011033
http://dx.doi.org/10.3390/cancers14164040
work_keys_str_mv AT binimarta realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT quesadastanislas realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT meeuspierre realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT rodriguesmanuel realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT leblanceric realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT floquetanne realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT pautierpatricia realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT marchalfrederic realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT provansalmagali realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT campionloic realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT causeretsylvain realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT gourgousophie realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT raycoquardisabelle realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT classejeanmarc realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT pomelchristophe realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT delamotterougethibault realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT barrangeremmanuel realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT savoyeaudemarie realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT guillemetcecile realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT gladiefflaurence realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT demarchimartin realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT rouzierroman realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT courtinardc realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT romeoclemence realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase
AT jolyflorence realworlddataonnewlydiagnosedbrcamutatedhighgradeepithelialovariancancersthefrenchnationalmulticenteresmedatabase